Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

20 Oct 2020

Abstract excerpt

Abstract Treatment-free remission (TFR) is one of the therapeutic goals for patients with chronic phase chronic myeloid leukemia (CML-CP). Although previous reports indicated that antitumor immunity contributes to TFR, its determinants are still unclear. We previously reported that allelic polymorphisms of killer immunoglobulin-like receptors (KIR) and human leukocyte antigens (HLA) are associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33082274
DOI: 10.1158/1535-7163.mct-20-0336

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaPMID 33082274Read ↗

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuationSemantic proximity Read ↗

Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia.Semantic proximity Read ↗

Allelic Polymorphisms of KIRs and HLAs Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML.Semantic proximity Read ↗

Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.Semantic proximity Read ↗

IFN‐α treatment may enable discontinuation of TKIs in NK cell‐licensed patients with CML‐CPSemantic proximity Read ↗

Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients.Semantic proximity Read ↗

Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.Semantic proximity Read ↗

Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patientsSemantic proximity Read ↗

Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.Semantic proximity Read ↗

Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patientsSemantic proximity Read ↗

NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib.Semantic proximity Read ↗

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.